Biomarkers, Pathways, and Targeted Therapies®
First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.
Most Popular Right Now
Precision Medicine in Oncology®
Precision Medicine—An Inevitable (Though Challenging) Goal!Andre Goy, MD, writes about implementing precision medicine, which requires a global effort from clinicians, insurance providers, government regulators, and the pharmaceutical industry.
Read more >>>